Core Scientific Statistics
Total Valuation
Core Scientific has a market cap or net worth of $7.01 billion. The enterprise value is $9.65 billion.
| Market Cap | 7.01B |
| Enterprise Value | 9.65B |
Important Dates
The last earnings date was Tuesday, July 28, 2026, before market open.
| Earnings Date | Jul 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Core Scientific has 321.34 million shares outstanding. The number of shares has increased by 3.62% in one year.
| Current Share Class | 321.34M |
| Shares Outstanding | 321.34M |
| Shares Change (YoY) | +3.62% |
| Shares Change (QoQ) | +0.75% |
| Owned by Insiders (%) | 1.91% |
| Owned by Institutions (%) | 105.69% |
| Float | 258.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.92 |
| Forward PS | 7.90 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 13.47 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 21.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.89
| Current Ratio | 0.89 |
| Quick Ratio | 0.65 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.91 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -2.43% |
| Return on Invested Capital (ROIC) | -9.62% |
| Return on Capital Employed (ROCE) | -15.43% |
| Weighted Average Cost of Capital (WACC) | 21.44% |
| Revenue Per Employee | $1.35M |
| Profits Per Employee | -$5.02M |
| Employee Count | 325 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Core Scientific has paid $2.73 million in taxes.
| Income Tax | 2.73M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +65.35% in the last 52 weeks. The beta is 5.50, so Core Scientific's price volatility has been higher than the market average.
| Beta (5Y) | 5.50 |
| 52-Week Price Change | +65.35% |
| 50-Day Moving Average | 25.06 |
| 200-Day Moving Average | 19.71 |
| Relative Strength Index (RSI) | 46.31 |
| Average Volume (20 Days) | 12,536,171 |
Short Selling Information
The latest short interest is 63.36 million, so 19.72% of the outstanding shares have been sold short.
| Short Interest | 63.36M |
| Short Previous Month | 69.09M |
| Short % of Shares Out | 19.72% |
| Short % of Float | 24.47% |
| Short Ratio (days to cover) | 5.33 |
Income Statement
In the last 12 months, Core Scientific had revenue of $440.31 million and -$1.63 billion in losses. Loss per share was -$5.07.
| Revenue | 440.31M |
| Gross Profit | 141.50M |
| Operating Income | -140.82M |
| Pretax Income | -1.43B |
| Net Income | -1.63B |
| EBITDA | -314.06M |
| EBIT | -388.89M |
| Loss Per Share | -$5.07 |
Balance Sheet
The company has $1.77 billion in cash and $4.41 billion in debt, with a net cash position of -$2.64 billion or -$8.21 per share.
| Cash & Cash Equivalents | 1.77B |
| Total Debt | 4.41B |
| Net Cash | -2.64B |
| Net Cash Per Share | -$8.21 |
| Equity (Book Value) | -2.42B |
| Book Value Per Share | -7.57 |
| Working Capital | -294.15M |
Cash Flow
In the last 12 months, operating cash flow was $520.24 million and capital expenditures -$1.48 billion, giving a free cash flow of -$957.75 million.
| Operating Cash Flow | 520.24M |
| Capital Expenditures | -1.48B |
| Depreciation & Amortization | 62.57M |
| Net Borrowing | 3.27B |
| Free Cash Flow | -957.75M |
| FCF Per Share | -$2.98 |
Margins
| Gross Margin | 32.14% |
| Operating Margin | -31.98% |
| Pretax Margin | -324.28% |
| Profit Margin | n/a |
| EBITDA Margin | -71.33% |
| EBIT Margin | -88.32% |
| FCF Margin | n/a |
Dividends & Yields
Core Scientific does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.62% |
| Shareholder Yield | -3.62% |
| Earnings Yield | -23.30% |
| FCF Yield | -13.67% |
Analyst Forecast
The average price target for Core Scientific is $36.56, which is 67.63% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $36.56 |
| Price Target Difference | 67.63% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | 78.47% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Core Scientific has an Altman Z-Score of -1.14 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.14 |
| Piotroski F-Score | 3 |